ArticleJournal of geriatric oncology2022
Disparities in older adult accrual to cancer trials: Analysis from the alliance for clinical trials in oncology (A151736).
Article in Journal of geriatric oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The value and effectiveness of geriatric assessments for older adults with cancer: an umbrella review.BMC geriatrics · 2024Pooled it
- Cancer incidence and mortality trends among older adults.npj aging · 2026Article
- Article
- Unveiling Factors Associated With Older Adult Accrual to Cancer Clinical Trials: Lessons From the ECOG-ACRIN Experience.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Article
- Ageing, immune fitness and cancer.Nature reviews. Cancer · 2025Review
- Patterns of presentation, treatment, and survival among older adults with metastatic breast cancer: Results from a large prospective registry.Journal of geriatric oncology · 2025Article
- The complex interplay between aging and cancer.Nature aging · 2025Review
- The role of social, economic, and medical marginalization in cancer clinical trial participation inequities: A systematic review.Journal of clinical and translational science · 2025Review
- Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020.Journal of the National Cancer Institute · 2024Article
- Fatigue-related symptom clusters and functional status of older adults in hospice.Palliative & supportive care · 2023Article
- Article
- Exclusion of Older Adults from Cancer Clinical Trials: Review of the Literature and Future Recommendations.Seminars in radiation oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundOlder adults are under-represented in cancer clinical trials. However, it remains unclear which types of trials under-enroll aging patients. We aimed to identify associations between trial characteristics and disparate enrollment of older adults onto trials sponsored by the Alliance for Clinical Trials in Oncology (Alliance).
methodsActual age ≥ 65 percentage and trial data were extracted from the Alliance closed study list. Each trial, based on its cancer type and years of enrollment, was assigned an expected age ≥ 65 percentage extracted from the Surveillance, Epidemiology, and End Results (SEER) US population-based database. Enrollment disparity difference (EDD), the difference between the expected age ≥ 65 percentage and the actual age ≥ 65 percentage, was calculated for each trial. Linear regression determined trial variables associated with larger EDDs and variables with an overall association p-value <0.20 were included in a multivariable fixed-effects linear model.
resultsThe median age of 66,708 patients across 237 trials was 60 years (range 18-102). The average actual age ≥ 65 percentage enrolled per trial was lower than each trial's expected age ≥ 65 percentage average (39% vs. 58%; EDD 19, 95% CI 17.1-21.3%, p < 0.0001). In multivariable analyses, non-genitourinary (GU) cancer types (p < 0.001), trimodality+ trials (estimate 8.78, 95%CI 2.21-15.34, p = 0.009), and phase 2 trials (estimate 4.43 95% CI -0.06-8.91; p = 0.05) were all associated with larger EDDs.
conclusionsDisparate enrollment of older adults is not equal across cancer trials. Future strategies to improve older adult inclusion should focus on trial types associated with the highest disparate enrollment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.